The effects of steroids should also be re-evaluated. Optimal treatment according to disease severity remains to be established.”
“Several endocrine abnormalities, including hypothyroidism and Cushing’s syndrome (CS), are considered as causative factors of obesity. The aim of this study was to evaluate the prevalence of endocrine disorders CP-868596 and obesity-associated co-morbidities, as well as the impact of substantial weight loss.
Screening was performed
in 433 consecutive morbidly obese patients (age 41 +/- 12 years; BMI 47 +/- 6.9 kg/m(2); women 76%). A 1-mg dexamethasone suppression test (1-mg DST) was conducted to exclude CS, and thyrotropin (TSH) was measured to exclude hypothyroidism. Insulin sensitivity was estimated from oral glucose
tolerance tests employing the Clamp-like index. Examinations were carried out at baseline, DAPT clinical trial as well as at 6 and 12 months postoperatively.
The prevalence of CS was below 0.6%. Before surgery, TSH was elevated compared to an age- and sex-matched normal weight control group (2.4 +/- 1.2 vs. 1.5 +/- 0.7 mu U/ml; p < 0.001). The NCEP criteria of metabolic syndrome (MetS) were fulfilled by 39.5% of the patients. Impaired glucose tolerance and diabetes mellitus were observed in 23.5% and 22.6%, respectively. Seventy-two percent were insulin resistant. During follow-up, weight (BMI 47 +/- 6.9 vs. 36 +/- 6.4 vs. 32 +/- 6.6 kg/m(2); p < 0.001) and TSH decreased significantly (2.4 +/- 1.2 vs. 1.8 +/- 1.0 vs. 1.8 +/- 1.0 mu U/ml; p < 0.001). Serum cortisol was higher in the MetS(+)-group compared to the MetS(-)-group (15.0 +/- 6.3 vs. 13.5 +/- 6.3 mu g/dl; p = 0.003).
CS appears to be a rare cause of morbid obesity. Normalization of
slightly elevated thyrotropin after weight loss suggests that obesity causes TSH elevation rather than the reverse.”
“BACKGROUND: Alternative dosing is often used clinically to address common barriers with statin therapy, such as intolerance and cost. Previous findings have demonstrated significant www.selleckchem.com/products/ON-01910.html and clinically similar reductions in low-density lipoprotein (LDL) cholesterol to daily dosing, when comparing similar total weekly doses.
OBJECTIVE: To determine whether rosuvastatin 80 mg once weekly produced comparable lipid and high-sensitivity C-reactive protein (hsCRP) changes to atorvastatin 10 mg daily, when measured at key points after last dose.
METHODS: This was a randomized, double-blind, parallel group, 8-week pilot study. Eligible subjects, 18 to 65 years of age, had documented dyslipidemia with LDL cholesterol >100 mg/dL and triglycerides <200 mg/dL. Participants were randomized to receive either rosuvastatin 80 mg once weekly (n = 10) or atorvastatin 10 mg daily (n = 10), for 8 weeks. Lipid panels and hsCRP were measured at baseline and 1-4 and 5-8 days after the last dose.